Literature DB >> 35133619

Spectrum of Genetic T-Cell Disorders from 22q11.2DS to CHARGE.

Daniel Urschel1,2,3, Vivian P Hernandez-Trujillo4,5,6.   

Abstract

Improved genetic testing has led to recognition of a diverse group of disorders of inborn errors of immunity that present as primarily T-cell defects. These disorders present with variable degrees of immunodeficiency, autoimmunity, multiple organ system dysfunction, and neurocognitive defects. 22q11.2 deletion syndrome, commonly known as DiGeorge syndrome, represents the most common disorder on this spectrum. In most individuals, a 3 Mb deletion of 22q11 results in haploinsufficiency of 90 known genes and clinical complications of varying severity. These include cardiac, endocrine, gastrointestinal, renal, palatal, genitourinary, and neurocognitive anomalies. Multidisciplinary treatment also includes pediatrics/general practitioners, genetic counseling, surgery, interventional therapy, and psychology/psychiatry. Chromosome 10p deletion, TBX1 mutation, CHD7 mutation, Jacobsen syndrome, and FOXN1 deficiency manifest with similar overlapping clinical presentations and T-cell defects. Recognition of the underlying disorder and pathogenesis is essential for improved outcomes. Diagnosing and treating these heterogenous conditions are a challenge and rapidly improving with new diagnostic tools. Collectively, these disorders are an example of the complex penetrance and severity of genetic disorders, importance of translational diagnostics, and a guide for multidisciplinary treatment.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  22q11.2 deletion syndrome; DiGeorge syndrome; Inborn errors of immunity; Primary immunodeficiency; T-cell immunodeficiency

Mesh:

Year:  2022        PMID: 35133619     DOI: 10.1007/s12016-022-08927-z

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   10.817


  11 in total

1.  Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome.

Authors:  Nashat Al-Sukaiti; Brenda Reid; Sasson Lavi; Daifulah Al-Zaharani; Adelle Atkinson; Chaim M Roifman; Eyal Grunebaum
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

2.  Live vaccine use and safety in DiGeorge syndrome.

Authors:  Annika M Hofstetter; Kathleen Jakob; Nicola P Klein; Cornelia L Dekker; Kathryn M Edwards; Neal A Halsey; Roger Baxter; S Elizabeth Williams; Philip L Graham; Philip LaRussa
Journal:  Pediatrics       Date:  2014-03-31       Impact factor: 7.124

Review 3.  An HDR (hypoparathyroidism, deafness, renal dysplasia) syndrome locus maps distal to the DiGeorge syndrome region on 10p13/14.

Authors:  P Lichtner; R König; T Hasegawa; H Van Esch; T Meitinger; S Schuffenhauer
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

4.  Live viral vaccines in a DiGeorge syndrome patient.

Authors:  V Waters; K S Peterson; P LaRussa
Journal:  Arch Dis Child       Date:  2006-06-23       Impact factor: 3.791

5.  First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases.

Authors:  M Louise Markert; José G Marques; Bénédicte Neven; Blythe H Devlin; Elizabeth A McCarthy; Ivan K Chinn; Adriana S Albuquerque; Susana L Silva; Claudio Pignata; Geneviève de Saint Basile; Rui M Victorino; Capucine Picard; Marianne Debre; Nizar Mahlaoui; Alain Fischer; Ana E Sousa
Journal:  Blood       Date:  2010-10-26       Impact factor: 22.113

6.  Heterozygous FOXN1 Variants Cause Low TRECs and Severe T Cell Lymphopenia, Revealing a Crucial Role of FOXN1 in Supporting Early Thymopoiesis.

Authors:  Marita Bosticardo; Yasuhiro Yamazaki; Jennifer Cowan; Giuliana Giardino; Cristina Corsino; Giulia Scalia; Rosaria Prencipe; Melanie Ruffner; David A Hill; Inga Sakovich; Irma Yemialyanava; Jonathan S Tam; Nurcicek Padem; Melissa E Elder; John W Sleasman; Elena Perez; Hana Niebur; Christine M Seroogy; Svetlana Sharapova; Jennifer Gebbia; Gary Ira Kleiner; Jane Peake; Jordan K Abbott; Erwin W Gelfand; Elena Crestani; Catherine Biggs; Manish J Butte; Nicholas Hartog; Anthony Hayward; Karin Chen; Jennifer Heimall; Filiz Seeborg; Lisa M Bartnikas; Megan A Cooper; Claudio Pignata; Avinash Bhandoola; Luigi D Notarangelo
Journal:  Am J Hum Genet       Date:  2019-08-22       Impact factor: 11.025

7.  TBX1 loss-of-function mutation contributes to congenital conotruncal defects.

Authors:  Min Zhang; Fu-Xing Li; Xing-Yuan Liu; Jing-Yi Hou; Shi-Hong Ni; Juan Wang; Cui-Mei Zhao; Wei Zhang; Ye Kong; Ri-Tai Huang; Song Xue; Yi-Qing Yang
Journal:  Exp Ther Med       Date:  2017-10-24       Impact factor: 2.447

8.  Microdeletion 22q11 and oesophageal atresia.

Authors:  M C Digilio; B Marino; P Bagolan; A Giannotti; B Dallapiccola
Journal:  J Med Genet       Date:  1999-02       Impact factor: 6.318

9.  Thymus transplantation for complete DiGeorge syndrome: European experience.

Authors:  E Graham Davies; Melissa Cheung; Kimberly Gilmour; Jesmeen Maimaris; Joe Curry; Anna Furmanski; Neil Sebire; Neil Halliday; Konstantinos Mengrelis; Stuart Adams; Jolanta Bernatoniene; Ronald Bremner; Michael Browning; Blythe Devlin; Hans Christian Erichsen; H Bobby Gaspar; Lizzie Hutchison; Winnie Ip; Marianne Ifversen; T Ronan Leahy; Elizabeth McCarthy; Despina Moshous; Kim Neuling; Malgorzata Pac; Alina Papadopol; Kathryn L Parsley; Luigi Poliani; Ida Ricciardelli; David M Sansom; Tiia Voor; Austen Worth; Tessa Crompton; M Louise Markert; Adrian J Thrasher
Journal:  J Allergy Clin Immunol       Date:  2017-04-08       Impact factor: 10.793

10.  The 11q Terminal Deletion Disorder Jacobsen Syndrome is a Syndromic Primary Immunodeficiency.

Authors:  Virgil A S H Dalm; Gertjan J A Driessen; Barbara H Barendregt; Petrus M van Hagen; Mirjam van der Burg
Journal:  J Clin Immunol       Date:  2015-11-14       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.